SLC52A1, solute carrier family 52 member 1, 55065

N. diseases: 160; N. variants: 0
Disease: Tumor Progression ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.040 Biomarker phenotype BEFREE We highlight recent insights into the ability of different protease agonists to bias PAR-2 signaling and the newly emerging evidence for an interplay between PAR-2 and membrane-anchored serine proteases, which may co-conspire to promote tumor progression and metastasis. 30610085 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.040 Biomarker phenotype BEFREE PAR2 has been associated with many aspects regarding tumor progression, such as the production of pro-tumoral cytokines. 30172372 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.040 Biomarker phenotype BEFREE Proteinase-activated receptors (PARs) are a subfamily of G protein-coupled receptors (GPCRs) with four members, PAR1, PAR2, PAR3 and PAR4, playing critical functions in hemostasis, thrombosis, embryonic development, wound healing, inflammation and cancer progression. 24215724 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression 		0.040 Biomarker phenotype BEFREE TF signaling involving PAR2 and integrins has multiple effects on angiogenesis and tumor progression. 20434002 2010